RetaMaps

MD Anderson Endocrine Center — Conor J. Best, MD

MD Anderson Endocrine Center (Main Building) · 1515 Holcombe Blvd · Houston, TX 77030

3.9· 808 Google reviews

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

About this practice

MD Anderson’s Endocrine Center (Department of Endocrine Neoplasia and Hormonal Disorders) is a cancer-center academic program for benign and malignant endocrine disease—thyroid cancer and thyroid disorders, adrenal and pituitary tumors, parathyroid disease, neuroendocrine tumors, MEN syndromes, and treatment-related endocrine complications including diabetes and metabolic bone disease. Care is delivered at the main Houston campus (1515 Holcombe Blvd) through MD Anderson appointment intake. Official faculty pages do not list GLP-1 weight-loss brands; this is oncologic/academic endocrinology, not a cash GLP-1 clinic.

Services & access

Advertises semaglutide todayNot listed
Advertises tirzepatide todayNot listed
Telehealth visits—
Cash pay acceptedYes
Accepts insurance — per practice websiteYes
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Review activity

★ 3.9
Google rating · 808 reviews
66
reviews in the past year (avg ★ 3.5)

Counts computed by RetaMaps from public Google reviews; most recent review 2026-09-26. Read the reviews themselves on the practice's Google listing.

Clinicians

  • Steven P. Weitzman, MD, FACE

Other locations of this practice

Nearby providers in Houston

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs